A comprehensive analysis of POLE/POLD1 genomic alterations in colorectal cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Mutations in POLE/POLD1 genes in colorectal cancer (CRC) are linked to a high tumor mutational burden (TMB-H). Identifying POLE/POLD1 short variant mutations is crucial for potential exceptional responses to immunotherapy.
Area Of Science
- Genomics
- Oncology
- Molecular Biology
Background
- Pathogenic mutations in POLE/POLD1 impair DNA replication fidelity, leading to a high tumor mutational burden (TMB-H).
- This TMB-H phenotype is observed independently of deficient mismatch repair (dMMR) and microsatellite instability-high (MSI-H) status.
Purpose Of The Study
- To investigate the frequency and characteristics of POLE/POLD1 alterations in colorectal cancer (CRC).
- To analyze the association between POLE/POLD1 mutations and tumor mutational burden (TMB), and identify co-occurring molecular alterations.
Main Methods
- Analysis of de-identified records from 9136 CRC patients profiled using the Tempus xT assay (DNA sequencing).
- Evaluation of POLE/POLD1 genomic alterations, including copy number variations and short variant mutations.
- Comparison of TMB and co-alteration profiles between POLE/POLD1 mutated and wild-type (WT) CRC samples.
Main Results
- POLE/POLD1 genomic alterations were found in 2.4% of CRC samples, with copy number loss being the most frequent type.
- POLE/POLD1 mutated patients showed a higher frequency of TMB-H (22% vs. 9% in WT, P < .001).
- Short variant mutations in POLE/POLD1 were associated with an ultra-hypermutated phenotype (median TMB 159 mut/Mb) and increased co-mutations in genes like APC, ALK, ATM, BRCA2, and RET.
Conclusions
- POLE/POLD1 mutations significantly impact immunological markers (TMB, MMR, MSI-H) and molecular co-alterations in CRC.
- A distinct subgroup with POLE/POLD1 short variant mutations (0.4% of all CRC) exhibits an ultra-hypermutated phenotype.
- Identification of this ultra-mutated subgroup is critical due to their potential for exceptional responses to immune checkpoint inhibitors.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...